当前位置: X-MOL 学术Am. J. Transplant. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Long-term follow-up of beta cell replacement therapy in 10 HIV-infected patients with renal failure secondary to type 1 diabetes mellitus.
American Journal of Transplantation ( IF 8.8 ) Pub Date : 2020-01-28 , DOI: 10.1111/ajt.15796
Garrett R Roll 1 , Andrew M Posselt 1 , Jonathan Freise 2 , Julia Baird 1 , Shareef Syed 1 , Sang Mo Kang 1 , Ryutaro Hirose 1 , Gregory L Szot 1 , Arya Zarinsefat 3 , Sandy Feng 1 , Giulia Worner 1 , Minnie Sarwal 1 , Peter G Stock 1
Affiliation  

The approach to transplantation in human immunodeficiency virus (HIV)‐positive patients has been conservative due to fear of exacerbating an immunocompromised condition. As a result, HIV‐positive patients with diabetes were initially excluded from beta cell replacement therapy. Early reports of pancreas transplant in patients with HIV described high rates of early graft loss with limited follow‐up. We report long‐term follow‐up of islet or pancreas transplantation in HIV‐positive type 1 diabetic patients who received a kidney transplant concurrently or had previously undergone kidney transplantation. Although 4 patients developed polyoma viremia, highly active antiretroviral therapy and adequate infectious prophylaxis were successful in providing protection until CD4+ counts recovered. Coordination with HIV providers is critical to reduce the risk of rejection by minimizing drug‐drug interactions. Also, protocols for prophylaxis of opportunistic infections and strategies for monitoring and treating BK viremia are important given the degree of immunosuppression required. This series demonstrates that type 1 diabetic patients with well‐controlled HIV and renal failure can be appropriate candidates for beta cell replacement, with a low rate of infectious complications, early graft loss, and rejection, so excellent long‐term graft survival is possible. Additionally, patients with HIV and cardiovascular contraindications can undergo islet infusion.

中文翻译:

对 10 名继发于 1 型糖尿病的肾功能衰竭的 HIV 感染患者进行 β 细胞替代疗法的长期随访。

由于担心会加剧免疫功能低下的情况,对人类免疫缺陷病毒 (HIV) 阳性患者进行移植的方法一直是保守的。因此,HIV 阳性的糖尿病患者最初被排除在 β 细胞替代疗法之外。HIV 患者胰腺移植的早期报告描述了早期移植物丢失率高且随访有限。我们报告了对同时接受肾移植或之前接受过肾移植的 HIV 阳性 1 型糖尿病患者进行胰岛或胰腺移植的长期随访。尽管有 4 名患者出现多瘤病毒血症,但高效的抗逆转录病毒疗法和充分的感染预防措施成功地提供了保护,直到 CD4+ 计数恢复。与 HIV 提供者的协调对于通过最大限度地减少药物相互作用来降低排斥风险至关重要。此外,鉴于所需的免疫抑制程度,预防机会性感染的方案以及监测和治疗 BK 病毒血症的策略也很重要。该系列表明,HIV 和肾功能衰竭控制良好的 1 型糖尿病患者可以成为 β 细胞替代的合适人选,感染并发症、早期移植物丢失和排斥反应发生率低,因此移植物长期存活率极佳。此外,患有 HIV 和心血管禁忌症的患者可以进行胰岛输注。鉴于所需的免疫抑制程度,预防机会性感染的方案以及监测和治疗 BK 病毒血症的策略非常重要。该系列表明,HIV 和肾功能衰竭控制良好的 1 型糖尿病患者可以成为 β 细胞替代的合适人选,感染并发症、早期移植物丢失和排斥反应发生率低,因此移植物长期存活率极佳。此外,患有 HIV 和心血管禁忌症的患者可以进行胰岛输注。鉴于所需的免疫抑制程度,预防机会性感染的方案以及监测和治疗 BK 病毒血症的策略非常重要。该系列表明,HIV 和肾功能衰竭控制良好的 1 型糖尿病患者可以成为 β 细胞替代的合适人选,感染并发症、早期移植物丢失和排斥反应发生率低,因此移植物长期存活率极佳。此外,患有 HIV 和心血管禁忌症的患者可以进行胰岛输注。因此,出色的长期移植物存活是可能的。此外,患有 HIV 和心血管禁忌症的患者可以进行胰岛输注。因此,出色的长期移植物存活是可能的。此外,患有 HIV 和心血管禁忌症的患者可以进行胰岛输注。
更新日期:2020-01-28
down
wechat
bug